Objective: Mitochondrial dysfunction subsequent to increased oxidative-stress and alterations in energy metabolism is considered to play a role in the development of cardiac hypertrophy and its progression to failure, though the sequence of events remain to be elucidated. This study aimed at characterizing the impact of hypertrophy development on the activity and expression of mitochondrial NADP + -isocitrate dehydrogenase (mNADP + -ICDH), a metabolic enzyme that controls redox and energy status. We expanded on our previous finding of its inactivation through post-translational modification by the lipid peroxidation product 4-hydroxynonenal (HNE) in 7-week-old spontaneously hypertensive rat (SHR) hearts, before hypertrophy development (Benderdour et al. J Biol Chem 278: 45154, 2003). In this study, we used 7-, 15-, and 30-week-old SHR and Sprague-Dawley (SD) rats with abdominal aortic coarctation. Results: Compared to age-matched control Wistar-Kyoto (WKY) rats, SHR hearts showed a significant 25% decrease of mNADP + -ICDH activity, which preceded in time (i) the decline in its protein and mRNA expression levels (between 10 and 35%), and (ii) the increase in hypertrophy markers. The chronic and persistent loss of mNADP + -ICDH activity in SHR was associated with enhanced tissue accumulation of HNE/mNADP + -ICDH and total HNE/protein adducts at all ages, and contrasted with the profile of changes in the activity of other mitochondrial enzymes involved in antioxidant or energy metabolism. Two-way ANOVA of the data revealed also a significant effect of age on most parameters measured in SHR and WKY rat hearts. The mNADP + -ICDH activity, protein and mRNA expression were reduced by 25 and 35% in coarctated SD rats, and were normalized by treatment of SHR or coarctated SD rats with renin-angiotensin system inhibitors, which prevented or attenuated hypertrophy. Conclusion: Our data show that cardiac mNADP + -ICDH activity and expression are differentially and sequentially affected in hypertrophy development and, to a lesser extent, with aging. Decreased cardiac mNADP + -ICDH activity, which is attributed at least in part to HNE adduct formation, appears to be a relevant early and persistent marker of mitochondrial oxidative stress-related alterations in hypertrophy development. Potentially, this could also contribute to the aetiology of cardiomyopathy.
INTRODUCTION
Cardiac hypertrophy, an early milestone in the clinical course of heart failure, is an independent risk factor for future cardiac events associated with mortality and morbidity. Increased oxidative stress and/or alterations of fuel metabolism are among factors that contribute to the development of cardiac hypertrophy and its progression to failure, regardless of etiology (3; 16; 29; 37; 58; 63) . Both factors could independently impair the capacity of the mitochondria to fulfil their crucial role in energy production necessary for contraction (42) and thereby contribute to the activation of signaling pathways governing cell death by apoptosis and/or necrosis (1; 9). However, additional work is needed to clarify how the various changes integrate themselves in relation with the various -adaptive and maladaptive -stages of the disease (from hypertrophy -compensated and decompensated -to failure). There is also a need to identify markers of the various stages of disease development to define more targeted therapies and to increase our ability to predict whether a given intervention will lead to beneficial or detrimental outcomes.
In a recent study, we obtained data in the spontaneously hypertensive rats (SHR) that are of potential relevance to our better understanding of the sequence of oxidative stress-related pathophysiological events linked to cardiac disease development. The SHR is a well-established model of genetic hypertension, which develops cardiac hypertrophy between 9 and 12 weeks of age (60) and show functional symptoms of decompensated hypertrophy after 18 to 24 months (47) . We found that mitochondrial NADP + -isocitrate dehydrogenase (mNADP + -ICDH), a metabolic enzyme controlling energy and redox status, is inactivated through 4-hydroxynonenal (HNE) adduct formation before hypertrophy development (5) . HNE, the major α,β-unsaturated aldehyde formed from free radical-induced peroxidation of ω-6 polyunsaturated fatty acids (24) , reacts readily with cysteine, lysine and histidine residues of proteins. While aldehydes have long been considered merely as markers of tissue damage, their role as "second toxic messengers", as initially hypothesized by Esterbauer et al. (25) , is becoming increasingly accepted. Indeed, it is now believed that aldehydes, and HNE among them, are responsible for many cytopathological effects observed during oxidative stress in vivo (13; 21; 41; 52; 55; 67; 74). In this regard, the results of our recent study emphasized the involvement of post-translational modifications of mitochondrial metabolic enzymes by HNE in the early oxidative stress-related events linked to cardiac hypertrophy development (5) .
Additional work is, however, necessary to assess the significance of cardiac mNADP + -ICDH inactivation caused by HNE binding within the context of disease development. Could mNADP + -ICDH inactivation be a marker and/or player in oxidative stress-related events during cardiac hypertrophy development? The mNADP + -ICDH, which catalyzes reversible interconversion between isocitrate and α-ketoglutarate, shows its highest activity and expression in the heart, where it is confined to cardiomyocytes (31; 36; 43; 72) . Another NADP + -ICDH isoform is located in the cytosol, but in the heart it represents <5% (54). The high level of homology of mNADP + -ICDH polypeptide and cDNA sequences between species (~95% between humans, pigs, cattle, mice and rats) (36; 45; 72) suggests that it may play a critical role in cellular metabolism. However, much remains to be learned about the role and regulation of mNADP + -ICDH, especially in the heart. There is a current resurgence of interest in this enzyme following the study by Jo et al. (37) in NIH3T3 cells, which supported its antioxidant role through the generation of NADPH (36) . However, an alternative role for this enzyme is also proposed, where it operates in the reverse direction, i.e. generating isocitrate and NADP + , thereby participating in a substrate cycle regulating citric acid cycle (CAC) activity (59). The latter role is specifically relevant in the heart (14) , where a high mitochondrial NADPH/NADP + ratio (>50 versus <1 in NIH3T3) could restrict CAC flux (crucial for contraction).
The objective of this study, which expands on our previous one (5) ; a generous gift from Merck-Fross, Montreal, Qc, Canada) in drinking water. This same subgroup of SHR was part of a previously-published study (20) . The body weights (g) of untreated and treated SHR at sacrifice were 314 ± 4 and 306 ± 5, respectively (n=6).
(ii)
Surgery model of cardiac disease: Heart tissue samples were obtained from 16-week-old SD rats 14 days after sham operation or after aortic coarctation with or without treatment with RAS inhibitor valsartan, an angiotensin II type I (AT 1 ) receptor antagonist. Data from this same sub-group of SD rats were obtained within the context of another study (4) . Briefly, after anesthesia with sodium pentobarbital, a 0.6 mm band was placed around the abdominal aorta. The controls had sham surgery without band insertion. A subgroup of SD rats underwent aortic coarctation and oral treatment with valsartan (10 mg x kg
); a generous gift from Novartis, Montreal, Qc, Canada). All rats were sacrificed 14 days after surgery. Body weights (g) at sacrifice were 379 ± 10, 379 ± 6 and 373 ± 4 (n=4) for rats that underwent sham surgery or coarctation with or without treatment, respectively.
Measurements of cardiomyocyte size:
The NIH image 1.61 program (http://rsb.info.nih.gov/nihimage/) served to measure the cross-sectional area of the ventricles as described previously (20) . 
Statistical analyses:
The data are expressed as means ± SEM. The statistical significance of differences between mean values at p < 0.05 was assessed by the unpaired t-test or one-way ANOVA, followed by the Bonferroni multiple-comparison post-test. Two-way ANOVA was used to test for significant differences in the effect of (i) hypertrophy development and progression in SHR, which we referred to as the disease factor throughout the text, (ii) age, and (iii) the interaction of disease x age. The Bonferroni multiple-comparison post-test was performed to assess significant differences in the effect of disease at 7, 15 and 30 weeks.
RESULTS

Studies of SHR
Myocardial ANF mRNA levels were significantly elevated in 15-and 30-week-old SHR compared to age-matched WKY rats ( Figure 1A ). To confirm the development of hypertrophy in SHR, cardiomyocyte size were measured in a number of heart tissue samples from SHR and WKY rats (n=3 of each strain). SHR hearts showed an increase in cardiomyocyte size ( Figure 1B) , and, according to two-way ANOVA, this effect of disease was significant and independent of age. and the CAC enzymes aconitase ( Figure 4B ), which is highly susceptible to free radical inactivation (50) , and citrate synthase ( Figure 4C ). Two-way ANOVA, showed a significant effect of disease on MnSOD and aconitase activity, which was independent of age for MnSOD. Compared to control WKY rat hearts, aconitase activity was reduced significantly in 7-and 30-, but not in 15-week-old SHR hearts ( Figure 4B ), while that of MnSOD was increased in 15-and decreased in 30-week-old SHR ( Figure 4A ). Two other antioxidant enzymes, GSH peroxidase and reductase, presented a diseaseage-dependent activity profile that was identical to that of MnSOD (data not reported). In contrast to the oxidative stress-related enzymes, tissue citrate synthase did not differ significantly between SHR and WKY rats, nor did its activity vary with age ( Figure 4C ). Altogether, the data from Figures 2 and 4 indicate that the profile of changes in mNADP + -ICDH activity in SHR with disease progression differs from that of measured antioxidant and energy metabolic enzymes.
Loss of mNADP + -ICDH activity and expression in SHR hearts is attenuated by treatment with a RAS inhibitor
We evaluated whether mNADP + -ICDH activity and expression in SHR hearts could be modulated by a drug that attenuates cardiac hypertrophy (20) . For this purpose, we analyzed heart tissues from 15-week-old SHR that had been exposed for 4 weeks to 30 mg x kg -1 x day -1 of enalapril, an ACE inhibitor (20) . In our earlier study, it was shown that such treatment decreased systolic blood pressure and induced regression of cardiac hypertrophy as reflected by a reduction of cardiac mass and DNA (20) .
As illustrated in Figure 5A , myocardial mNADP + -ICDH activity in enalapril-treated SHR was 1. 
Studies of SD rats subjected to aortic coarctation
We considered it was essential to exclude the possibility that changes in mNADP could also occur at extra-mitochondrial sites and diffuse within the cells to propagate damage to the mitochondria. In SHR, enhanced superoxide anion production, reported as early as 4 weeks, has been attributed to dysfunctional nitric oxide synthase activity and/or angiotensin II-stimulated NAD(P)H oxidase activity (15; 17; 44; 56; 73) . However, the contribution of the various site(s) of HNE formation remains to be clarified.
In our study, we considered it essential to address the confounding effect of hypertrophy development and age in SHR. Indeed, both conditions are characterized by mitochondrial dysfunction subsequent to increased oxidative stress and energy deficits (18; 42) . For this purpose, the data were analyzed by two-way ANOVA, which revealed an effect of disease on mNADP + -ICDH activity and protein, though not on mRNA expression levels that was independent of age. However, our analysis also detected a significant effect of age on all parameters presented in Figures 2 and 3 . An agedependent accumulation of HNE/protein adducts in the mitochondria ( Figure 3B ) has been reported recently by other investigators (46; 62) . Collectively, these findings concur with the notion of progressive oxidative stress enhancement with age. The fact that two-way ANOVA revealed an interaction between disease and age for this parameter supports the notion that these two conditions share some oxidative stress-related components.
The chronic loss of mNADP MnSOD, GSH peroxidase and reductase provided only partial protection against the increased oxidative stress. In fact, other detoxification enzymes could be differentially affected by disease. In fact, hearts from SHR were shown to have a lower capacity to metabolize exogenous HNE than those of WKY rats (28) . Furthermore, in a dog model of pacing-induced heart failure, a progressive and sequential decline in activity and expression at the protein and mRNA levels was reported for aldose reductase, an enzyme proposed to be involved in HNE detoxification (61) . We recognize that several factors should be kept in mind in the interpretation of data of our study. Indeed, for our measurements, we used whole heart tissue homogenates. While cardiomyocytes represent >85% of the heart cell mass, the heart contains also non-contractile cells (33) and (5)). Therefore, in the short term, changes in mNADP + -ICDH activity may be considered partly adaptive, but in the long term, they would be maladaptive leading to mitochondrial energy deficits. Interestingly, when perfused ex vivo in the working mode, 15-week-old SHR hearts maintain functional parameters that are similar to control Wistar or WKY rats (68), though they show an impaired capacity to respond and withstand an acute adrenergic stimulation (39),
suggesting that hypertrophy development in these rats include some maladaptive components.
In conclusion, the major findings of this study can be summarized as follows. The mNADP predominantly occurring at cysteine residues (5), could potentially be reversed by aldehydesequestering drugs (12; 19; 22; 32) . In fact, the reversal of HNE binding to proteins could be part of the mechanism by which N-acetylcysteine prevents cardiac hypertrophy in rats infused with angiotensin II (48) . Finally, additional work appears also warranted to expand on the interesting peripheral finding of this study, namely that hypertrophy and aging results in similar directional changes in mNADP+-ICDH activity and expression.
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